In general, the combination of mutations in NPM1 and IDH (either IDH1 or IDH2) is considered a favorable profile, especially for those AML patients destined to be treated with VEN plus HMA [77,89]. This evidence concerns the gene IDH1 and acute myeloid leukemia.